Tests for suspected Hodgkin lymphoma: biopsy, staging, and treatment preparation

An enlarged neck node, night sweats, or unexplained fever can lead to an assessment for Hodgkin lymphoma, but symptoms alone cannot establish the diagnosis. Infection, inflammatory conditions, and other cancers can produce similar findings. The first purpose of testing is to identify the nature of the abnormal tissue. It is reasonable to ask what each test will answer and which result is expected to determine the next step.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

The clinician will ask when the lump appeared, whether it is growing, and whether there has been a recent infection or treatment with antibiotics or steroids. Describe weight change with the approximate starting weight and timing, and explain whether you were trying to lose weight. For night sweats, describe whether clothing or bedding becomes soaked. A short timeline can be more informative than saying that you have felt unwell for several months.
In typical Hodgkin lymphoma staged with an appropriate PET/CT, a separate marrow biopsy is not routine for every patient. The decision depends on the imaging, unexplained blood-count abnormalities, and whether the finding would change management. Another patient's investigation list is not a reason to insist on exactly the same procedure. [S2]
Prepare complete pathology reports and addenda, an inventory of available tissue, original PET/CT files, dated laboratory results, and an accurate medication history. Translation should preserve uncertainty, units, and dates. “Suspicious for” must not become “confirmed” in another language. Record whether any investigation took place after steroids or chemotherapy, because that timing may change its interpretation.

Quick answer

Full guide

The workup usually has three linked parts: obtaining tissue for diagnosis, mapping disease distribution, and assessing fitness for the intended treatment. Some appointments can happen in parallel. However, breathlessness, substantial face or neck swelling, or difficulty lying flat warrants prompt clinical assessment. Waiting for a routine scan or an overseas appointment should not delay evaluation of possible compression or another urgent complication.

History and examination guide the investigation

The clinician will ask when the lump appeared, whether it is growing, and whether there has been a recent infection or treatment with antibiotics or steroids. Describe weight change with the approximate starting weight and timing, and explain whether you were trying to lose weight. For night sweats, describe whether clothing or bedding becomes soaked. A short timeline can be more informative than saying that you have felt unwell for several months.

Examination assesses the distribution of nodes, general health, and possible liver or spleen enlargement. Pain, firmness, and mobility of a lump cannot individually confirm or exclude cancer. Ultrasound may help characterize and locate a superficial node or guide sampling, but an ultrasound description of an abnormal lymph node is not the final diagnosis. Bring earlier imaging and laboratory results so that the team can see whether the findings have changed. [S1]

Why an adequate lymph node biopsy matters

In classical Hodgkin lymphoma, the malignant cells may be a small minority within a substantial inflammatory background. Tissue architecture therefore helps the pathologist interpret the abnormal cells. An excisional lymph node biopsy is preferred when feasible; a core needle biopsy can be appropriate when excision is not practical or safe. The chosen site should balance diagnostic yield with bleeding, anesthesia, and access risks. [S2]

A fine-needle aspirate collects relatively few cells and may suggest an abnormality without resolving the diagnosis. Even a core or surgical specimen can be inadequate if it contains extensive necrosis or misses the representative part of the lesion. A recommendation to obtain more tissue does not automatically imply that the first procedure was performed incorrectly. It may reflect the need for a more dependable basis for treatment.

Before the procedure, disclose anticoagulants, antiplatelet drugs, allergies, and previous anesthesia problems. The procedural team should decide how medicines are managed; do not stop them independently. Avoid starting steroids simply to shrink a lump without medical direction. If steroids were necessary for an urgent problem, document the dose and dates so that the pathologist can take the exposure into account.

Pathology is an interpretation, not one positive marker

The final diagnosis combines cell appearance, the surrounding tissue, and immunostains. CD30 is commonly expressed in classical Hodgkin lymphoma, but it is not unique to this disease. CD15, PAX5, CD20, and other findings must be interpreted together. Nodular lymphocyte-predominant disease, anaplastic large cell lymphoma, and certain mediastinal B-cell tumors may need to be distinguished in difficult cases. Their treatment pathways can differ substantially. [S2]

For a second pathology opinion, the receiving laboratory may need original slides, paraffin blocks, or unstained sections, rather than a translated report alone. Ask exactly what material is required, how it should be labeled, and whether it will be returned. Patient identity, specimen location, collection date, and accession number should stay linked. A clear inventory prevents a review of the wrong specimen or unnecessary repeat sampling.

PET/CT establishes distribution and a reference point

After tissue confirmation, PET/CT is commonly used for staging and provides a baseline for response comparison. It combines metabolic activity with anatomical information. Increased uptake can also occur with inflammation or infection, so a PET finding is not equivalent to a biopsy diagnosis. PET may help identify a suitable biopsy site, but does not replace adequate tissue when the disease itself remains uncertain. [S28]

Follow the nuclear medicine service's preparation instructions about fasting, activity, and glucose management. People with diabetes should ask in advance how insulin and other medicines fit with the appointment. Report recent infection, vaccination, growth-factor injections, pregnancy, or possible pregnancy. Whether intravenous CT contrast or a separate diagnostic CT is needed depends on the clinical question. Do not assume that every PET/CT includes the same type of CT examination.

Keep the original imaging files, usually in DICOM format, as well as the written report. A few photographed slices cannot show the complete pattern of disease or reliably support comparison at another hospital. If the planned treatment depends on an interim PET result, establishing access to the baseline study before the first infusion is especially useful.

Blood tests assess health but cannot rule out lymphoma

A complete blood count identifies anemia and other blood-cell changes. Liver and kidney tests inform treatment planning, while inflammatory markers and additional laboratory findings may contribute to risk assessment. Some people have substantial abnormalities, while others have relatively normal routine blood results at diagnosis. A normal tumor-marker panel or the absence of visible malignant cells in a blood sample does not exclude Hodgkin lymphoma. [S1]

Infection screening is selected according to local practice, medical history, and the proposed regimen, often including hepatitis and HIV assessment. A positive result needs interpretation: it may represent previous exposure, current infection, or another status requiring clarification. It does not automatically mean cancer treatment is impossible. Coordination between the lymphoma team and an infection specialist can establish monitoring, prevention, or treatment where needed.

Ask whether each laboratory result is still recent enough for the decision ahead. Tests obtained before a significant illness or several rounds of treatment may no longer describe current fitness. Repeating a safety test close to an infusion can therefore be appropriate even when an earlier copy is available.

Is a bone marrow biopsy always required?

In typical Hodgkin lymphoma staged with an appropriate PET/CT, a separate marrow biopsy is not routine for every patient. The decision depends on the imaging, unexplained blood-count abnormalities, and whether the finding would change management. Another patient's investigation list is not a reason to insist on exactly the same procedure. [S2]

If marrow sampling is recommended, ask whether the team is investigating suspected lymphoma involvement, a separate blood disorder, or an unexplained abnormal count. That purpose explains why additional sampling may be useful despite existing imaging. Marrow findings also have sampling limitations and need to be interpreted with the broader evidence. A negative sample should not be treated as a universal answer to every abnormality seen elsewhere.

Heart, lung, and immune-treatment preparation

Doxorubicin-containing treatment requires consideration of cardiac risk, often including echocardiography when appropriate. If bleomycin is contemplated, lung history, current respiratory symptoms, and relevant pulmonary function or imaging findings need review. Mention smoking exposure, previous lung infection, and any oxygen requirement. The tests and monitoring schedule should reflect the intended drugs and the person's actual risk factors. [S1][S5]

Before PD-1 treatment, the clinician reviews relevant organ function, including thyroid status, and asks about autoimmune disease, transplantation, and immunosuppressive medicines. China's official antitumor-drug guidance emphasizes baseline assessment and ongoing monitoring for treatment response and toxicity. Baseline tests cannot predict every adverse event, but they help distinguish an established problem from a new treatment-related change. [S7]

Do not equate a normal pretreatment test with a guarantee that a drug cannot cause harm. New cough, breathlessness, persistent diarrhea, or marked weakness still deserves assessment during treatment. Equally, an abnormal baseline result may lead to specialist advice or a modified plan rather than automatic exclusion from all effective therapy.

Age, pregnancy, and fertility affect the workup

Children and adolescents should be assessed by a team familiar with age-appropriate Hodgkin protocols. Adult doses, radiation fields, and follow-up assumptions should not simply be copied into pediatric care. Even when a newer regimen has an approval covering a particular age, the child's pathology, stage, and full treatment pathway still need checking. Growth and long-term health are part of the planning. [S29]

Tell the team about pregnancy or the possibility of pregnancy before investigations involving radiation or medicines that could affect a fetus. People who may want biological children should be offered an early fertility discussion. Semen assessment and sperm preservation may be relevant for men; ovarian reserve assessment and preservation options may be relevant for women. No single laboratory test can promise or rule out a future pregnancy. These investigations should support an individual decision before treatment, when feasible. [S10][S11]

Question tests that have no clear decision attached

Not every newly diagnosed patient needs broad tumor sequencing, repeated tumor-marker panels, or multiple invasive investigations. Additional testing should resolve a diagnostic uncertainty, determine eligibility for a relevant study, or change treatment. Promising research methods are not automatically established requirements for all patients with classical Hodgkin lymphoma. [S2][S23]

For an optional paid test, ask what categories of result it can produce, what the team would do differently for each result, whether existing tissue is sufficient, and whether waiting could delay necessary care. If the answer will not affect the present decision, discuss whether the test can be deferred. More testing is not intrinsically more informative when the results have no defined clinical use.

Make a cross-hospital review efficient

Prepare complete pathology reports and addenda, an inventory of available tissue, original PET/CT files, dated laboratory results, and an accurate medication history. Translation should preserve uncertainty, units, and dates. “Suspicious for” must not become “confirmed” in another language. Record whether any investigation took place after steroids or chemotherapy, because that timing may change its interpretation.

A receiving hospital may reasonably repeat outdated blood tests, complete its own safety assessment, or obtain a new specimen to resolve an unanswered question. Ask for the reason for each repeated item. Pathology review, image review, a new PET study, and another biopsy are separate services with separate charges. Until there is a hospital quotation, a China testing budget should list unconfirmed items in renminbi rather than inventing a universal package price. [S12]

Before leaving the consultation, know who will assemble the final diagnostic conclusion, when the next result discussion is expected, and which symptoms should bring you back sooner. Update the team if health changes while results are pending. The purpose of investigation is a sufficiently reliable diagnosis and treatment plan, not the largest possible collection of reports.